{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:34:21Z","timestamp":1793115261000,"version":"4.5.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"\n Importance<\/jats:title>\n Advances in tumor immunology and vaccine technology are reshaping cancer vaccine development after decades of limited clinical success. More than 2000 immunogenic tumor proteins or antigens have been identified, the types of immune responses required for tumor eradication have been defined, and safe and effective vaccine delivery technologies have been developed. This progress has renewed clinical investigation of cancer vaccines for multiple types of cancer.<\/jats:p>\n <\/jats:sec>\n \n Observations<\/jats:title>\n \n Vaccines, such as those against human papillomavirus and hepatitis B, are composed of (1) an antigen target, (2) an adjuvant to activate the immune system, and (3) a vaccine delivery vehicle. Antigens can be derived from tumor mutations termed\n neoantigens<\/jats:italic>\n , or cancer-associated nonmutated proteins, which are normal human proteins that are abnormally expressed in cancer. The tumor can also act as an antigen source, such as when immunization occurs with whole tumor cells or by directly injecting an immunogenic substance into the tumor to elicit an adaptive immune response. T and B lymphocytes, cells of the adaptive immune system, are stimulated by cancer vaccines and can provide a highly specific and durable immune response directed against cancer. Vaccines that elicit adaptive immunity are approved for cancer treatment. Sipuleucel-T, a vaccine against the antigen prostatic acid phosphatase, reduced all-cause mortality compared with placebo in men with metastatic castrate-resistant prostate cancer (32% vs 23%; hazard ratio, 0.78 [95% CI, 0.61-0.98];\n P<\/jats:italic>\n \u2009=\u2009.03). Compared with granulocyte-macrophage colony-stimulating factor, a systemic immune stimulant, talimogene laherparepvec increased rates of a 6-month or longer complete or partial response, defined as the disappearance of all treated disease and at least a 50% decrease in the sum of the products of perpendicular diameters of the measurable lesion with no new lesions, respectively, when injected into advanced melanoma lesions (16.3% [95% CI, 12.1%-20.5%] vs 2.1% [95% CI, 0%-4.5%]; odds ratio, 8.9;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Most cancer vaccines have mild adverse effects, such as fatigue, fever, and injection site reactions. Combining cancer vaccines with chemotherapy or immunotherapy can increase the magnitude of the immune response and potentially result in greater reduction in cancer size. Combining the personalized mutation-based messenger RNA (mRNA) vaccine (mRNA-4157) with the immune checkpoint inhibitor pembrolizumab for resected high-risk stage IIIB to IV cutaneous melanoma improved relapse-free survival compared with pembrolizumab alone (76.6% vs 60%; hazard ratio, 0.56 [95% CI, 0.31-1.02];\n P<\/jats:italic>\n \u2009=\u2009.05). Cancer vaccines are undergoing evaluation in clinical trials to prevent cancer recurrence and for primary cancer prevention.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Cancer vaccines can treat several types of malignant neoplasms, including melanoma, prostate cancer, and bladder cancer. Adverse effects associated with cancer vaccines are generally mild and of short duration, promoting eventual integration of vaccination into treatment regimens with chemotherapy and immunotherapy. Cancer vaccines are increasingly undergoing evaluation for primary prevention.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.15540","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:30:55Z","timestamp":1790004655000},"page":"1454","source":"Crossref","is-referenced-by-count":0,"title":["Vaccines for Cancer"],"prefix":"10.1001","volume":"336","author":[{"given":"Mary L.","family":"Disis","sequence":"first","affiliation":[{"name":"Cancer Vaccine Institute, UW Medicine, Seattle, Washington"},{"name":"Division of Hematology and Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brie M. N.","family":"Chun","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Institute, UW Medicine, Seattle, Washington"},{"name":"Clinical Division, Fred Hutch Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiranjit K.","family":"Dhillon","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Institute, UW Medicine, Seattle, Washington"},{"name":"Division of Hematology and Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Liao","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Institute, UW Medicine, Seattle, Washington"},{"name":"Division of Gynecologic Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Hunter","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Institute, UW Medicine, Seattle, Washington"},{"name":"Division of Hematology and Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise L.","family":"Cecil","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Institute, UW Medicine, Seattle, Washington"},{"name":"Division of Hematology and Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10441","key":"jrv260021r1","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","article-title":"Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.","volume":"403","author":"Shattock","year":"2024","journal-title":"Lancet"},{"issue":"14","key":"jrv260021r2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer.","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv260021r3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/vaccines10050793","article-title":"The global impact of hepatitis B vaccination on hepatocellular carcinoma.","volume":"10","author":"Flores","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"jrv260021r4","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis.","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"1","key":"jrv260021r5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms.","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"jrv260021r6","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1634\/theoncologist.2010-0307","article-title":"Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.","volume":"16","author":"Miles","year":"2011","journal-title":"Oncologist"},{"issue":"22","key":"jrv260021r7","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 Peptide vaccine and interleukin-2 in patients with advanced melanoma.","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv260021r8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial.","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"issue":"12","key":"jrv260021r9","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.3390\/cancers15123251","article-title":"DCVax-L vaccination in patients with glioblastoma: real promise or negative trial? the debate is open.","volume":"15","author":"Gatto","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"31","key":"jrv260021r10","doi-asserted-by":"publisher","first-page":"18627","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-? signaling.","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"jrv260021r11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder.","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv260021r12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study.","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"jrv260021r13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"jrv260021r14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1359725","article-title":"Mechanism of action of nadofaragene firadenovec-vncg.","volume":"14","author":"Narayan","year":"2024","journal-title":"Front Oncol"},{"issue":"7","key":"jrv260021r15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/1078-0432.CCR-24-2812","article-title":"FDA approval summary: nadofaragene firadenovec-vncg for bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer.","volume":"31","author":"Colbert","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"25","key":"jrv260021r16","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"jrv260021r17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012446","article-title":"Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.","volume":"13","author":"Hayes","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"3","key":"jrv260021r18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001621","article-title":"Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.","volume":"9","author":"Malvehy","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"jrv260021r19","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/ijc.25449","article-title":"Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras.","volume":"128","author":"Wed\u00e9n","year":"2011","journal-title":"Int J Cancer"},{"issue":"4","key":"jrv260021r20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"10427","key":"jrv260021r21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"7963","key":"jrv260021r22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"8056","key":"jrv260021r23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer.","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"issue":"3","key":"jrv260021r24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41591-025-04182-9","article-title":"Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b\/2 trial.","volume":"32","author":"D\u2019Alise","year":"2026","journal-title":"Nat Med"},{"issue":"1","key":"jrv260021r25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13073-024-01388-3","article-title":"Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients.","volume":"16","author":"Zhang","year":"2024","journal-title":"Genome Med"},{"issue":"12","key":"jrv260021r26","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.20.03452","article-title":"Phase II randomized study of CMB305 and atezolizumab compared with atezolizumab alone in soft-tissue sarcomas expressing NY-ESO-1.","volume":"40","author":"Chawla","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"jrv260021r27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"jrv260021r28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol"},{"issue":"26","key":"jrv260021r29","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2015.66.3955","article-title":"Efficacy of tumor vaccines and cellular immunotherapies in non-small-cell lung cancer: a systematic review and meta-analysis.","volume":"34","author":"Dammeijer","year":"2016","journal-title":"J Clin Oncol"},{"key":"jrv260021r30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2020.10.014","article-title":"Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: a 20-year systematic review and meta-analysis.","volume":"142","author":"Dafni","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"jrv260021r31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer.","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"jrv260021r32","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv260021r33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamaoncol.2022.5143","article-title":"Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 nonrandomized clinical trial.","volume":"9","author":"Disis","year":"2023","journal-title":"JAMA Oncol"},{"key":"jrv260021r34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682492","article-title":"Telomerase as a target for therapeutic cancer vaccines and considerations for optimizing their clinical potential.","volume":"12","author":"Ellingsen","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"jrv260021r35","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"jrv260021r36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-023-01776-0","article-title":"Molecular mimicry and cancer vaccine development.","volume":"22","author":"Tagliamonte","year":"2023","journal-title":"Mol Cancer"},{"issue":"22","key":"jrv260021r37","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2174\/0113816128364722250126172914","article-title":"Cancer drug targeting: molecular mechanism, approaches, and regulatory framework.","volume":"31","author":"Chandel","year":"2025","journal-title":"Curr Pharm Des"},{"issue":"1","key":"jrv260021r38","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.1038\/s41598-022-17950-1","article-title":"Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer.","volume":"12","author":"Cecil","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"jrv260021r39","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-13-3286","article-title":"Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.","volume":"74","author":"Cecil","year":"2014","journal-title":"Cancer Res"},{"issue":"18","key":"jrv260021r40","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1158\/1078-0432.CCR-13-2671","article-title":"Is the \u201c3+3\u201d dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? a recommendation for alternative design.","volume":"20","author":"Rahma","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"jrv260021r41","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1245\/s10434-014-3794-3","article-title":"Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.","volume":"21","author":"Hu","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"jrv260021r42","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-15-2507","article-title":"Targeting carcinoembryonic antigen with DNA vaccination: on-target adverse events link with immunologic and clinical outcomes.","volume":"22","author":"McCann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"jrv260021r43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.743448","article-title":"Longitudinal high-throughput sequencing of the T-cell receptor repertoire reveals dynamic change and prognostic significance of peripheral blood TCR diversity in metastatic colorectal cancer during chemotherapy.","volume":"12","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"jrv260021r44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13058-015-0584-1","article-title":"Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.","volume":"17","author":"Datta","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"1","key":"jrv260021r45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000328","article-title":"Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapy.","volume":"3","author":"Obeng","year":"2024","journal-title":"BMJ Oncol"},{"issue":"16","key":"jrv260021r46","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1158\/1078-0432.CCR-14-2334","article-title":"Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome.","volume":"21","author":"GuhaThakurta","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"jrv260021r47","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2372118","article-title":"Modulation of blood T cell polyfunctionality and HVEM\/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients.","volume":"13","author":"Dalle","year":"2024","journal-title":"Oncoimmunology"},{"issue":"1","key":"jrv260021r48","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41698-025-01084-4","article-title":"Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent\/metastatic head and neck cancer.","volume":"9","author":"Ruiz-Torres","year":"2025","journal-title":"NPJ Precis Oncol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2854262\/jama_disis_2026_rv_260021_1792526027.84705.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:00:33Z","timestamp":1793113233000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2854262"}},"subtitle":["A Translational Science Review"],"short-title":[],"issued":{"date-parts":[[2026,10,27]]},"references-count":48,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.15540","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,27]]}}}